Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 14-33

  Walsh, Jennifer ^a   Cram, Anne ^b   Woertz, Katharina ^c   Breitkreutz, Joerg ^c   Winzenburg, Gesine ^d   Turner, Roy ^d   Tuleu, Catherine ^e  

^a Jenny Walsh Consulting Limited   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dosage form; Excipient; Formulation; Paediatric; Palatability; Taste masking

Indexed keywords

DRUG DELIVERY; MEDICINE;

DOSAGE FORMS; EXCIPIENT; FORMULATION; PALATABILITY; TASTE-MASKING;

PEDIATRICS;

BITTER TASTE ANTAGONIST; CYCLODEXTRIN; EXCIPIENT; FLAVORING AGENT; LIPID; POLYMER; RECEPTOR BLOCKING AGENT; RESIN; SWEETENING AGENT; UNCLASSIFIED DRUG; ACESULFAME; ADENOSINE PHOSPHATE; ALITAME; BUSPIRONE; CINNAMIC ACID; CYCLAMATE SODIUM; DICLOFENAC; ERYTHRITOL; FLAVONE DERIVATIVE; IBUPROFEN; ION EXCHANGE RESIN; ISOMALT; LACTITOL; LIPOPROTEIN; MALTITOL; MANNITOL; NEOHESPERIDIN; NEOTAME; SACCHARIN; SORBITOL; STEVIOSIDE; SUCRALOSE; SUCROSE; THAUMATIN; TRAMADOL; UNINDEXED DRUG; XYLITOL; DRUG;

BITTER TASTE; CHILD; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MARKETING; DRUG PELLET; DRUG SOLUBILITY; EXCIPIENT COMPATIBILITY; HUMAN; MASKING; NONHUMAN; PALATABILITY; PH MEASUREMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; SAFETY; TASTE BUD; TASTE MASKING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; MEDICATION COMPLIANCE; SWEETNESS; TASTE AVERSION; TASTE PREFERENCE; DRUG EFFECTS; MEDICINAL CHEMISTRY; PEDIATRICS; TASTE; TOXICITY;

CHEMISTRY, PHARMACEUTICAL; CHILD; EXCIPIENTS; FLAVORING AGENTS; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; TASTE;

EID: 84902318119     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.02.012     Document Type: Review

References (146)

1. Periodic Survey #44 Patient compliance with prescription regimens, American Academy of Pediatrics (Last accessed 26 March 2013). http://www.aap.org/en-us/professional-resources/Research/Pages/PS44_Executive_Summary_PatientCompliancewithPrescriptionRegimens.aspx.
2. Matsui D. Current issues in pediatric medication adherence. Pediatr. Drugs 2007, 9(5):283-288.
3. Mennella J.A., Pepino M.Y., Reed D.R. Genetic and environmental determinants of bitter perception and sweet preferences. Pediatrics 2005, 115(2):e216-e222. (Feb.).
4. Mennella J.A., Beauchamp G.K. Optimizing oral medications for children. Clin. Ther. 2008, 30:2120-2132.
5. Committee for Medicinal Products for Human Use (CHMP), Paediatric Committee (PDCO) EMA/CHMP/QWP/805880/2012 Rev. Guideline on pharmaceutical development of medicines for paediatric use (Last accessed 23 January 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf.
6. Cohen R., de La Rocque F., Lécuyer A., Wollner C., Bodin M.J., Wollner A. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur. J. Pediatr. 2009, 168(7):851-857.
7. Wollner A., Lécuyer A., De La Rocque F., Sedletzki G., Derkx V., Boucherat M., Elbez A., Gelbert-Baudino N., Levy C., Corrard F., Cohen A. Acceptability, compliance and schedule of administration of oral antibiotics in outpatient children. Arch. Pediatr. 2011, 18(5):611-616.
8. Regulation EC No. 1901/2006 (Last accessed 26 March 2013). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:378:0001:0019:en:PDF.
9. Ayenew Z., Puri V., Kumar L., Bansal A.K. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat. Drug Deliv. Formul. 2009, 3:26-39.
10. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin. Drug Deliv. 2007, 4:417-426.
11. Sohi H., Sultana Y., Khar R.K. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev. Ind. Pharm. 2004, 30:429-448.
12. Lipchock S.V., Reed D.R., Mennella J.A. Relationship between bitter-taste receptor genotype and solid medication formulation usage among young children: a retrospective analysis. Clin. Ther. 2012, 34(3):728-733.
13. Biever C. Bitter pills banished by taste-blocking compounds, New Scientist (Last accessed 10 Feb 2013). http://www.newscientist.com/article/dn3433-bitter-pills-banished-by-tasteblocking-compounds.html.
14. Modifying Bitterness: Mechanism, Ingredients and Applications 1997, Technomic Publishing Company. G.M. Roy (Ed.).
15. McGregor R. Bitter blockers in foods and pharmaceuticals. Modifying Flavour in Food 2007, 221-231. Woodhead Publishing. A. Taylor, J. Hort (Eds.).
16. Redpoint Bio website (Last accessed 10 Feb 2013). http://www.redpointbio.com/science_taste.shtml.
17. McGregor R. Future directions: using biotechnology to discover new sweeteners, bitter blockers and sweetness potentiators. Optimising Sweet Taste in Foods 2006, 404-414. CRC Press. W.J. Spillane (Ed.).
18. Mennella J.A., Pepino M.Y., Beauchamp G.K. Modification of bitter taste in children. Dev. Psychobiol. 2003, 43(2):120-127. (Sep).
19. Deshpande D.A., Wang W.C.H., McIlmoyle E.L., Robinett K.S., Schillinger R.M., An S.S., Sham J.S.K., Liggett S.B. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat. Med. 2010, 16:1299-1304.
20. Ming D., Ninomiya Y., Margolskee R.F. Blocking taste receptor activation of gustducin inhibits gustatory responses to bitter compounds. PNAS 1999, 96(17):9903-9908.
21. Keast R.S.J., Breslin P.A.S. Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts. Pharm. Res. 2002, 19(7):1019-1026.
22. in-Pharma Technologist.com, Bitter blocker backed by FDA (Last accessed 10 Feb 2013). http://www.in-pharmatechnologist.com/Regulatory-Safety/Bitter-blocker-backed-by-FDA.
23. Weller P.J. Neohesperidan dihydrochalcone. Handbook of Pharmaceutical Excipients 2012, 518-519. Pharmaceutical Press, London & Philadelphia. R.C. Rowe, P.J. Shenskey, W.G. Cook, M.E. Fenton (Eds.).
24. Mitchell H. Sweeteners and Sugar Alternatives in Food Technology 2006, Wiley-Blackwell, Oxford. first edition.
25. International Sweeteners Association Neohesperidin DC Fact Sheet (Last accessed 10 Feb 2013). http://www.isabru.org/pdf/Neohesperidine_DC_August_2009_EN.pdf.
26. Naturex website Last accessed 10 Feb 2013. http://www.thaumatinnaturally.com/.
27. Ley J.P., Krammer G., Reinders G., Gatfield I.L., Bertram H.J. Evaluation of bitter masking flavanones from Herba Santa (Eriodictyon californicum (H. and A.) Torr., Hydrophyllaceae). J. Agric. Food Chem. 2005, 53(15):6061-6066.
28. J.A. Riemer, Kraft General Foods, Bitterness inhibitors. United States Patent 5,336,513 (1994).
29. Inglett G.E., Dowling B., Albrecht J.J., Hoglan F.A. Taste-modifying properties of miracle fruit (Synsepalum dulcificum). J. Agric. Food Chem. 1965, 13(3):284-287.
30. Wikipedia, The Free Encyclopedia, Synespalum dulcificum (Last accessed 10 Feb 2013). http://en.wikipedia.org/wiki/Synsepalum_dulcificum.
31. Wilken M.K., Satiroff B.A. Pilot study of "miracle fruit" to improve food palatability for patients receiving chemotherapy. Clin. J. Oncol. Nurs. 2012, 16(5):173-177.
32. Paladino A., Costantini S., Colonna G., Facchiano A.M. Molecular modelling of miraculin: structural analyses and functional hypotheses. Biochem. Biophys. Res. Commun. 2008, 367(1):26-32.
33. Piao J., Min B.C., Sakamoto K. Study of evoked potentials induced by stimulus of four basic tastes under the influence of miracle fruit. Jpn. J. Taste Smell Res. 1998, 5(3):391-394.
34. Mundada A.S., Chachda N.O., Avari J.G. Taste masking approaches - a review: part II. Am. Pharm. Rev. 2008, 11(6):74-82.
35. Tisi D.A. The taste of success. Pharm. Formul. Qual. 2009, 11(2):14-18.
36. Food and Drug Administration (FDA) List of food additives that are generally recognized as safe (GRAS) (Last accessed 28 March 2013). http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rpt=scogsListing.
37. DeFer B. Food ingredients - sweetener technical overview and allowable daily intake (ADI) 2010, 22. The NutraSweet Company, Chicago.
38. Sweeteners, Leatherhead Ingredients Handbook 2007, John Wiley & Sons, New York. third ed. R. Wilson (Ed.).
39. Mundada A.S., Jain S., Chachda N.O., Avari J.G. Taste masking approaches - a review: part I. Am. Pharm. Rev. 2008, 11(4):94-102.
40. Regulation EU/872/2012 and EU/873/2012 (Last accessed 18 March 2013). http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2012:267:SOM:EN:HTML.
41. CHMP, EMEA Reflection paper: Formulation of choice for the paediatric population (Last accessed 28 March 2013). http://www.emea.europa.eu/pdfs/human/paediatrics/19481005en.pdf.
42. Abdulla S., Amuri B., Kabanywanyi A.M., Ubben D., Reynolds C., Pascoe S., Fitoussi S., Yeh C.M., Nuortti M., Séchaud R., Kaiser G., Lefèvre G. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar. J. 2010, 3(9):253.
43. FLAVORx (Last accessed 18 March 2013). http://flavorx.com/.
44. Aires C.P., Tabchoury C.P., Del Bel Cury A.A., Koo H., Cury J.A. Effect of sucrose concentration on dental biofilm formed in situ and on enamel demineralization. Caries Res. 2006, 40(1):28-32.
45. Grabitske H.A., Slavin J.L. Gastrointestinal effects of low-digestible carbohydrates. Crit. Rev. Food Sci. Nutr. 2009, 49(4):327-360. (Apr).
46. EC Notice to applicants. Volume 3B Guidelines, Medicinal products for human use. Safety, environment and information. Excipients in the label and package leaflet of medicinal products for human use (Last accessed 18 March 2013). http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003412.pdf.
47. EMA/CHMP/SWP/888239/2011 Concept paper on the need for revision of the guideline on excipients in the label and package leaflet of medicinal products for human use (Last accessed 18 March 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/03/WC500123804.pdf.
48. Grotz V.L., Munro I.C. An overview of the safety of sucralose. Regul. Toxicol. Pharmacol. 2009, 55:1-5.
49. Brusick D., Borzelleca J.F., Gallo M., Williams G., Kille J., Hayes A.W., Pi-Sunyer F.X., Williams C., Burks W. Expert panel report on a study of Splenda in male rats. Regul. Toxicol. Pharmacol. 2009, 55:6-12.
50. Abou-Donia M.B., El-Masry E.M., Abdel-Rahman A.A., McLendon R.E., Schiffman S.S. Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J. Toxicol. Environ. Health A 2008, 71(21):1415-1429.
51. G.J. Wyley, MXPA008720 (2004).
52. Y.J. Park, D.S. Kang, WO2004096214 (2004).
53. Hagen T.A. CN1697648 2005.
54. A. Reiner, G.Reiner, US Patent 7 482,377 (2009).
55. S. Motola, A.R. Branfman, G.R. Agisim, D.J. Quirk, US Patent 502862 (1991).
56. J.W. Rayburn, WO2000012067A1 (2003).
57. Neves B.G., Farah A., Lucas E., de Sousa V.P., Maia L.C. Are paediatric medicines risk factors for dental caries and dental erosion?. Community Dent. Health 2010, 27(1):46-51. (Mar).
58. Keny R.V., Desouza C., Lourenco C.F. Formulation and evaluation of rizatriptan benzoate mouth disintegrating tablets. Indian J. Pharm. Sci. 2010, 72:79-85.
59. Singh I., Rehni A.K., Kalra R., Joshi G., Kumar M., Aboul-Enein H.Y. Ion exchange resins: drug delivery and therapeutic applications. FABAD J. Pharm. Sci. 2007, 32:91-100.
60. Srikanth M.V., Sunil S.A., Rao N.S., Uhumwangho M.U., Ramana Murthy K.V. Ion-exchange resins as controlled drug delivery carriers. J. Sci. Res. 2010, 2:597-611.
61. Gut F., Schiek W., Haefeli W.E., Walter-Sack I., Burhenne J. Cation exchange resins as pharmaceutical carriers for methylene blue: binding and release. Eur. J. Pharm. Biopharm. 2008, 69:582-587.
62. Ben-Aryeh H., Lapid S., Szargel R., Benderly A., Gutman D. Composition of whole unstimulated saliva of human infants. Arch. Oral Biol. 1984, 29:357-362.
63. Cogulu D., Sabah E., Kutukculer N., Ozkinay F. Evaluation of the relationship between caries indices and salivary secretory IgA, salivary pH, buffering capacity and flow rate in children with Down's syndrome. Arch. Oral Biol. 2006, 51:23-28.
64. Schneider H.J., Dedek W., Grahl R., Mothes B., Uhlemann J., Schwarz H., Schwachulla G., Reuter H., Möhring M. Studies of the persorption of large particles from radio-labelled cation exchangers. Urol. Int. 1983, 38:116-120.
65. Becker B.A., Swift J.G. Effective reduction of the acute toxicity of certain pharmacologic agents by use of synthetic ion exchange resins. Toxicology 1959, 1:42-54.
66. Agarwal R., Mittal R., Singh A. Studies of ion-exchange resin complex of chloroquine phosphate. Drug Dev. Ind. Pharm. 2000, 26:773-776.
67. Chatap V.K., Sharma D.K., Deshmukh P.T., Gupta V.B. Taste masking property of ion exchange resin: a review. Pharmatimes 2008, 40:22-26.
68. Shah R.B., Tawakkul M.A., Sayeed V.A., Khan M.A. Complexation between risperidone and Amberlite resin by various methods of preparation and binding study. Drug Dev. Ind. Pharm. 2009, 35:1409-1418.
69. Wagh V.D., Ghadlinge S.V. Taste masking methods and techniques in oral pharmaceuticals: current perspectives. J. Pharm. Res. 2009, 2:1049-1054.
70. Patra S., Samantaray R., Pattnaik S., Barik B.B. Taste masking of etoricoxib by using ion-exchange resin. Pharm. Dev. Technol. 2010, 15:511-517.
71. Bhalekar M.R., Bidkar S.J., Shete T.K., Madgulkar A.R. Taste masking of cefuroxime axetil by ion exchange resin complex. Lat. Am. J. Pharm. 2010, 29:198-204.
72. Huda I.S.G., Toshinwal S.S. Taste masked orodispersible tablet of atomoxetine hydrochloride. Lat. Am. J. Pharm. 2011, 30:1785-1791.
73. Samprasit W., Opanasopit P., Akkaramongkolporn P., Ngawhirunpat T., Wongsermsin K., Panomsuk S. Preparation and evaluation of taste-masked dextromethorphan oral disintragrating tablet. Pharm. Dev. Technol. 2012, 17:315-320.
74. Schornick E. Entwicklung und Herstellung geschmacksmaskierter Zubereitungen von Methylenblau-Resinaten zur Behandlung von Kindern mit Malaria 2011, (Ph.D. thesis), Heinrich Heine University Düsseldorf, Germany.
75. Geetha Rao C.G., Motiwale A.V., Satyanarayana D., Subrahmanyam E.V.S. Formulation of taste masked oral suspension of quinine sulphate by complexation. Indian J. Pharm. Sci. 2004, 6:329-331.
76. Madgulkar A.R., Bhalekar M.R., Padalkar R.R. Formulation design and optimization of novel taste masked mouth-dissolving tablets of tramadol having adequate mechanical strength. AAPS PharmSciTech 2009, 10:574-581.
77. Puttewar T.Y., Kshirsagar M.D., Chandewar A.V., Chikhale R.V. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. J. King Saudi Univ. Sci. 2010, 22(4):229-240.
78. Shukla D., Chakraborty S., Singh S., Mishra B. Fabrication and evaluation of taste masked resinate of risperidone and its orally disintegrating tablets. Chem. Pharm. Bull. 2009, 57:337-345.
79. Jain S.P., Mehta D.C., Shah S.P., Singh P.P., Amin P.D. Melt-in-mouth pellets of fexofenadine hydrochloride using crospovidone as an extrusion-spheronisation aid. AAPS PharmSciTech 2010, 11:917-923.
80. Malke S., Shidhaye S., Kadam V. Novel melt granulation using sugars for metoclopramide hydrochloride orally disintegrating tablet. Asian J. Pharm. Clin. Res. 2009, 2:68-72.
81. Venkatesh D.P., Geetha Rao C.G. Formulation of taste masked orodispersible tablets of ambroxol hydrochloride. Asian J. Pharm. 2008, 2:261-264.
82. Bhise K., Shaikh S., Bora D. Taste mask, design and evaluation of an oral formulation using ion exchange resins as drug carrier. AAPS PharmSciTech 2008, 9:557-562.
83. Roblegg E., Dittrich P., Haltmeyer K., Zimmer A. Reformulation of a codeine phosphate liquid controlled-release product. Drug Dev. Ind. Pharm. 2010, 36:1454-1462.
84. Cook W. Cyclodextrins. Handbook of Pharmaceutical Excipients 2012, 229-233. Pharmaceutical Press, London & Philadelphia. R.C. Rowe, P.J. Shenskey, W.G. Cook, M.E. Fenton (Eds.).
85. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. 2004, 3:1023-1035.
86. Szejtli J., Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm. 2005, 61(3):115-125.
87. Arima H., Higashi T., Motoyama K. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Ther. Deliv. 2012, 3(5):633-644.
88. Barrow P.C., Olivier P., Marzin D. The reproductive and developmental toxicity profile of beta-cyclodextrin in rodents. Reprod. Toxicol. 1995, 9(4):389-398.
89. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86(2):147-162.
90. Thackaberry E.A., Kopytek S., Sherratt P., Trouba K., McIntyre B. Comprehensive investigation of hydroxypropyl methylcellulose, propylene glycol, polysorbate 80 and hydroxypropyl-beta-cyclodextrin for use in general toxicology studies. Toxicol. Sci. 2010, 117(2):485-492.
91. Flourié B., Molis C., Achour L., Dupas H., Hatat C., Rambaud J.C. Fate of ß-cyclodextrin in the human intestine. J. Nutr. 1993, 123:676-680.
92. Al-Omran M.F., Al-Suwaych S.A., El-Helw A.M., Saleh S.I. Taste masking of diclofenac sodium employing four different techniques. Saudi Pharm. J. 2002, 10(3):106-113.
93. Binello A., Cravotto G., Nano G.M., Spagliardi P. Synthesis of chitosan-clyclodextrin adducts and evaluation of their bitter-masking properties. Flavour Fragance J. 2004, 19:394-400.
94. Binello A., Robaldo B., Barge A., Cavalli R., Cravotto G. Synthesis of cyclodextrin-based polymers and their use as debittering agents. J. Appl. Polym. Sci. 2008, 107:2549-2557.
95. Shah P.P., Mashru R.C. Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate. AAPS PharmSciTech 2008, 9(3):1025-1030.
96. Patel A.R., Vavia P.R. Preparation and evaluation of taste masked famotidine formulation using drug/ß-cyclodextrin/polymer ternary complexation approach. AAPS PharmSciTech 2008, 9(2):544-550.
97. Shah P.P., Mashru R.C. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation. Pharm. Dev. Technol. 2010, 15(3):276-285.
98. Mahesh A., Shastri N., Sadanandam M. Development of taste masked fast disintegrating films of levocetirizine dihydrochloride for oral use. Curr. Drug Deliv. 2010, 7:21-27.
99. Mady F.M., Abou-Taleb A.E., Khaled K.A., Yamasaki K., Iohara D., Ishiguro T., Hirayama F., Uekama K., Otagiri M. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-ß-CyD/povidone K30 complexation approach. J. Pharm. Sci. 2010, 99(10):4285-4294.
100. Birhade S.T., Bankar V.H., Gaikwad P.D., Pawar S.P. Preparation and evaluation of cyclodextrin based binary systems for taste masking. Int. J. Pharm. Sci. Drug Res. 2010, 2(3):199-203.
101. Sevukarajan M., Bachala T., Nair R. Novel inclusion complexes of oseltamivir phosphate-with ß cyclodextrin: physico-chemical characterization. J. Pharm. Sci. Res. 2010, 2(9):583-589.
102. Ono N., Miyamoto Y., Ishiguro T., Motoyama K., Hirayama F., Iohara D., Seo H., Tsuruta S., Arima H., Uekama K. Reduction of bitterness of antihistaminic drugs by complexation with ß-cyclodextrins. J. Pharm. Sci. 2011, 100(5):1935-1943.
103. Xu J., Bovet L.L., Zhao K. Taste masking microspheres for orally disintegrating tablets. Int. J. Pharm. 2008, 359(1-2):63-69.
104. Al-Omran M.F., Al-Suwayeh S.A., El-Helw A.M., Saleh S.I. Taste masking of diclofenac sodium using microencapsulation. J. Microencapsul. 2002, 19(1):45-52.
105. Hashimoto Y., Tanaka M., Kishimoto H. Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine. J. Pharm. Pharmacol. 2002, 54:1323-1328.
106. Guhmann M., Preis M., Gerber F., Pollinger N., Breitkreutz J., Weitschies W. Development of oral taste masked diclofenac formulations using a taste sensing system. Int. J. Pharm. 2012, 438(1-2):81-90.
107. L. Dobetti, Fast disintegrating tablets, US Patent 6,596,311 (2003).
108. Vaassen J., Bartscher K., Breitkreutz J. Taste masked lipid pellets with enhanced release of hydrophobic active ingredient. Int. J. Pharm. 2012, 429:99-103.
109. Jannin V., Cuppok Y. Hot-melt coating with lipid excipients. Int. J. Pharm. 2012, 10.1016/j.ijpharm.2012.10.026.
110. Maniruzzaman M., Boateng J.S., Bonnefille M., Aranyos A., Mitchell J.C., Douroumis D. Taste masking of paracetamol by hot-melt extrusion: an in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2012, 80(2):433-442.
111. Gryczke A., Schminke S., Maniruzzaman M., Beck J., Douroumis D. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surf., B 2011, 80(2):275-284.
112. Joint expert committee for food additives (JECFA) Toxicological evaluation of certain food additives and contaminants. WHO Food Additives Series, No. 26, nos 680-693 (Last accessed 29 March 2013.). http://www.inchem.org/pages/jecfa.html.
113. Eisele J., Haynes G., Rosamilia T. Characterisation and toxicological behaviour of basic methacrylate copolymer for GRAS evaluation. Regul. Toxicol. Pharm. 2011, 61:32-43.
114. Eisele J., Haynes G., Kreuzer K., Rosamilia T. Characterisation and toxicological assessment of neutral methacrylate copolymer for GRAS evaluation. Regul. Toxicol. Pharmacol. 2013, 67:392-408.
115. Hodge H.C. The chronic toxicity of cellulose acetate phthalate in rats and dogs. J. Pharmacol. Exp. Ther. 1944, 80:250-255.
116. Kayumba P.C., Huyghebaert N., Cordella C., Ntawukuliryayo J.D., Vervaet C., Remon J.P. Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue. Eur. J. Pharm. Biopharm. 2007, 66:460-465.
117. Kayumba P.C., Twagirumukiza M., Huyghebaert N., Ntawukuliryayo J.D., van Bortel L., Vervaet C., Remon J.P. Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria. Ann. Trop. Paediatr. 2008, 28:103-109.
118. Shirai Y., Sogo K., Yamamoto K., Kojima K., Fujioka H., Makita H., Nakamura Y. A novel fine granule system for masking bitter taste. Biol. Pharm. Bull. 1993, 16:172-177.
119. Hamashita T., Nakagawa Y., Aketo T., Watano S. Granulation of core particles suitable for film coating by agitation fluidized bed I. Optimum formulation for core particles and development of a novel friability test method. Chem. Pharm. Bull. 2007, 55:1169-1174.
120. Hamashita T., Matsuzaki M., Ono T., Ono M., Tsunenari Y., Aketo T., Watano S. Granulation of core particles suitable for film coating by agitation fluidized bed II. A proposal of a rapid dissolution test for evaluation of bitter taste of ibuprofen. Chem. Pharm. Bull. 2008, 56:883-887.
121. Lu M.F., Borodkin S., Woodward L., Li P., Diesner C., Hernandez L., Vadnere M. A polymer carrier system for taste masking of macrolide antibiotics. Pharm. Res. 1991, 8:706-712.
122. Cerea M., Zheng W., Young C.R., McGinity J.W. A novel powder coating process for attaining taste masking and moisture protective films applied to tablets. Int. J. Pharm. 2004, 279:127-139.
123. Pearnchob N., Siepmann J., Bodmeier R. Pharmaceutical applications of shellac: moisture-protective and taste-masking coatings and extended-release matrix tablets. Drug Dev. Ind. Pharm. 2003, 29:925-938.
124. Kondo K., Niwa T., Ozeki Y., Ando M., Danjo K. Preparation and evaluation of orally rapidly disintegrating tablets containing taste-masked particles using one-step dry-coated tablets technology 2011, 59(10):1214-1224.
125. Chivate A., Sargar V., Nalawade P., Tawde V. Formulation and development of oral dry suspension using taste masked Ornidazole particles prepared using Kollicoat-Smartseal 30D. Drug Dev. Ind. Pharm. 2013, 39(7). 935-935.
126. Balducci A.G., Colombo G., Corace G., Cavallari C., Rodriguez L., Buttini F., Colombo P., Rossi A. Layered lipid microcapsules for mesalazine delayed-release in children. Int. J. Pharm. 2011, 421(2):293-300.
127. Repka M.A., Shah S., Lu J.N., Maddineni S., Morott J., Patwardhan K., Mohammed N.N. Melt extrusion: process to product. Expert Opin. Drug Deliv. 2012, 9(1):105-125.
128. Erni W., Zeller M., Poit N. Die Eignung von Fettpellets als zwischenform für perorale depotarzneiformen. Acta Pharm. Technol. 1980, 26:165-171.
129. Savolainen M., Herder J., Khoo C., Lovqvist K., Dahlqvist C., Glad H., Juppo A.M. Evaluation of polar lipid-hydrophilic polymer microparticles. Int. J. Pharm. 2003, 262(1-2):47-62.
130. Passerini N., Albertini B., Perissutti B., Rodriguez L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int. J. Pharm. 2006, 318(1-2):92-102.
131. Pallagi E., Vass K., Pintye-Hodi K., Kasa P., Falkay G., Eros I., Szabo-Revesz P. Iron(II) sulfate release from drop-formed lipophilic matrices developed by special hot-melt technology. Eur. J. Pharm. Biopharm. 2004, 57(2):287-294.
132. Faham A., Prinderre P., Faran N., Eichler K.D., Kalantzis G., Joachim J. Hot-melt coating technology. I. Influence of Compritol 888ATO and granule size on theophylline release. Drug Dev. Ind. Pharm. 2000, 26:167-176.
133. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
134. N'Goma J.C.B., Amara S., Dridi K., Jannin V., Carriere F. Understanding the lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. Ther. Deliv. 2012, 3(1):105-124.
135. Suzuki H., Onishi H., Takahashi Y., Iwata M., Machida Y. Development of oral acetaminophen chewable tablets with inhibited bitter taste. Int. J. Pharm. 2003, 251:123-132.
136. Suzuki H., Onishi H., Hisamatsu S., Masuda K., Takahashi Y., Iwata M., Machida Y. Acetaminophen-containing chewable tablets with suppressed bitterness and improved oral feeling. Int. J. Pharm. 2004, 278:51-61.
137. Bold S., Boegershausen A., Rusch O., Graner O., Klein S. Hot Melt Coating with Fast Release as an Innovative Taste Masking Concept AAPS (Last accessed 28 March 2013). http://abstracts.aapspharmaceutica.com/Verify/AAPS2012/postersubmissions/W4090.pdf.
138. Kraahs P., Bold S., Fahsel L. EP 2 198 859 A1 2012.
139. Faham A., Prinderre P., Piccerelle P., Farah N., Joachim J. Hot melt coating technology: influence of Compritol (R) 888 Ato and granule size on chloroquine release. Pharmazie 2000, 55(6):444-448.
140. Patil A., Chafle S., Khobragade D., Umathe S., Avari J. Evaluation of hot melt coating as taste masking tool. Int. Res. J. Pharm. 2011, 2:169-172.
141. Sugao H., Yamazaki S., Shiozawa H., Yano K. Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax-coated microparticles. J. Pharm. Sci. 1998, 87(1):96-100.
142. Krause J. Novel paediatric formulations for the drug sodium benzoate 2008, (Ph.D. Thesis), Heinrich-Heine-University, Duesseldorf, Germany.
143. Witzleb R., Kanikanti V.R., Hamann H.J., Kleinebudde P. Solid lipid extrusion with small die diameters - electrostatic charging, taste masking and continuous production. Eur. J. Pharm. Biopharm. 2011, 77(1):170-177.
144. Michalk A. Taste masking by solid lipid extrusion 2007, (Ph.D. Thesis), Heinrich-Heine-University, Duesseldorf, Germany.
145. Cram A., Breitkreutz J., Desset-Brethes S., Nunn T., Tuleu C. Challenges of developing palatable oral paediatric formulations. Int. J. Pharm. 2009, 365(1-2):1-3.
146. Sam T., Ernest T.B., Walsh J., Williams J.L. A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms - an application for paediatric dosage form selection. Int. J. Pharm. 2012, 435(2):115-123.